New anti-clotting drugs linked to lower risk of serious bleeding

July 4, 2018, British Medical Journal

New drugs known as direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

The findings provide initial reassurance about the safety of DOACs as an alternative to warfarin for all new patients.

For many years, warfarin has been the main treatment for potentially fatal , known as venous thromboembolism (VTE). But DOACs are increasingly being used as an alternative to warfarin because patients don't need regular tests to check if they have the right amount of drug in their bloodstream.

Clinical trials have shown a reduced or similar risk of major bleeding for DOACs compared with warfarin. But such trials involve only carefully selected patients, so bleeding rates often do not reflect those seen in everyday ("real world") clinical practice.

Furthermore, most observational studies have included only patients with irregular heartbeat (atrial fibrillation or AF), creating an information gap for patients without this condition.

So researchers at the University of Nottingham supported by National Institute of Health Research set out to investigate the risks and benefits associated with the three commonest types of DOACs (dabigatran, rivaroxaban, and ) compared with warfarin in patients with and without AF.

Using data from two large UK primary care databases, they identified 196,061 patients who started or restarted anticoagulants (after more than a 12 month gap) between 2011 and 2016.

A total of 132,231 patients were taking warfarin, 7,744 dabigatran, 37,863 rivaroxaban, and 18,223 apixaban. Overall 53% (103,270) were diagnosed with AF and 47% (92,791) were prescribed anticoagulants for other conditions.

Patients were monitored for major bleeds leading to hospital admission or death, ischaemic stroke, VTE, and death from any cause ("all cause mortality").

After taking account of several known risk factors, the researchers found that apixaban was associated with a lower risk of major bleeding, particularly brain and gastric bleeds, in patients with and without AF, compared with warfarin.

They also found a lower risk of brain bleeds associated with use of dabigatran in patients with AF—and with use of rivaroxaban in patients without AF—compared with warfarin.

Rivaroxaban and low dose apixaban were, however, associated with increased risks of deaths from any cause in all patients when compared with warfarin, which may reflect closer monitoring of patients taking warfarin or may be related to other underlying conditions, suggest the researchers.

Overall, apixaban had the lowest numbers needed to treat over six months to avoid one extra major bleed (182 patients with AF and 138 without), compared with . In contrast, rivaroxaban had the lowest numbers needed to harm to observe one extra death (202 with AF and 61 without).

The researchers point out that this is an observational study, so no firm conclusions can be drawn about cause and effect, and they outline some limitations, such as possible misclassification due to patients not taking their medication.

Nevertheless, they say their study shows that "the risk of is lower in apixaban users regardless of the reason for prescribing, appearing to show apixaban to be the safest drug."

"Our results give an initial, reassuring, indication of the risk patterns for all taking anticoagulants, in particular with respect to those prescribed apixaban," they conclude.

Explore further: For dialysis patients with AFib, a newer blood thinner may provide a safer option

More information: Risks and benefits of direct anticoagulants versus warfarin in a real world setting: cohort studies using two primary care databases, BMJ (2018). www.bmj.com/content/362/bmj.k2505

Related Stories

For dialysis patients with AFib, a newer blood thinner may provide a safer option

June 29, 2018
People with irregular heartbeat due to a condition called atrial fibrillation, are often prescribed blood thinners to reduce the risk of blood clots that can cause a stroke. But for those who are also on dialysis for kidney ...

New anti-clotting drugs not associated with higher risk of major bleeding

October 17, 2017
A new group of drugs used to treat patients with serious blood clots are not associated with a higher risk of major bleeding compared with the older anti-clotting drug, warfarin, finds a study published by The BMJ today.

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Anticoagulants used for arrhythmia can have different thrombus formation rates

August 24, 2017
Anticoagulants are recommended for atrial fibrillation due to the high risk of stroke. However, bleeding complications can occur as a side effect. Researchers in Japan examined several types of anticoagulants and found that ...

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

January 17, 2017
(HealthDay)—For patients with newly diagnosed atrial fibrillation (AF), inpatient costs are lower with dabigatran and rivaroxaban than with warfarin, according to a letter published online in the Jan. 24 issue of the Journal ...

Recommended for you

'Good cholesterol' may not always be good

July 19, 2018
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) - also known as 'good cholesterol' - according to a study led by researchers in the University of Pittsburgh Graduate ...

Using adrenaline in cardiac arrests results in less than 1 percent more people leaving hospital alive

July 18, 2018
A clinical trial of the use of adrenaline in cardiac arrests has found that its use results in less than 1% more people leaving hospital alive—but almost doubles the risk of severe brain damage for survivors of cardiac ...

Omega 3 supplements have little or no heart or vascular health benefit: review

July 17, 2018
New evidence published today shows there is little or no effect of omega 3 supplements on our risk of experiencing heart disease, stroke or death.

Researchers discover new genes associated with heart function

July 17, 2018
A new study from an international research team, led by Dr. Yalda Jamshidi at St George's, University of London, has identified new genes associated with heart function and development.

Southern diet could be deadly for people with heart disease

July 12, 2018
People with a history of heart disease who eat a traditional Southern diet are more likely to die than those who follow a Mediterranean dietary pattern, according to new research.

Late-life high blood pressure may harm the brain, study says

July 11, 2018
Decades ago, hundreds of nuns and priests made an extraordinary decision: They agreed to donate their brains upon death to science, hoping to help solve mysteries about Alzheimer's and other diseases. Now, a study that used ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.